Mary Bates, PhD

Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.

Treated immune cells function properly to kill more bacteria, depending on the treatment and the bacteria.

A retrospective chart review suggests early spirometry is associated with shorter length of stay.

A study finds that CFTR mutation analysis is being ordered before (or without) sweat chloride in some cases, potentially leading to missed diagnoses, increased patient anxiety and unnecessary costs.